These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

56 related articles for article (PubMed ID: 1541877)

  • 21. A new high-performance liquid chromatographic method for determination of warfarin enantiomers.
    Osman A; Arbring K; Lindahl TL
    J Chromatogr B Analyt Technol Biomed Life Sci; 2005 Nov; 826(1-2):75-80. PubMed ID: 16143572
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Warfarin or acenocoumarol: which is better in the management of oral anticoagulants?
    Barcellona D; Vannini ML; Fenu L; Balestrieri C; Marongiu F
    Thromb Haemost; 1998 Dec; 80(6):899-902. PubMed ID: 9869157
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Influence of vinpocetine on warfarin-induced inhibition of coagulation.
    Hitzenberger G; Sommer W; Grandt R
    Int J Clin Pharmacol Ther Toxicol; 1990 Aug; 28(8):323-8. PubMed ID: 2272713
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
    Piver MS
    Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Colorectal cancer screening in young patients with poor health and severe comorbidity.
    Sultan S; Conway J; Edelman D; Dudley T; Provenzale D
    Arch Intern Med; 2006 Nov; 166(20):2209-14. PubMed ID: 17101938
    [TBL] [Abstract][Full Text] [Related]  

  • 26. NTP Toxicology and Carcinogenesis Studies of 3,4-Dihydrocoumarin (CAS No. 119-84-6) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1993 Sep; 423():1-336. PubMed ID: 12616288
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Retrospective evaluation of a method to predict fresh-frozen plasma dosage in anticoagulated patients.
    Frazee LA; Bourguet CC; Gutierrez W; Elder-Arrington J; Elackattu AE; Haller NA
    Am J Ther; 2008; 15(2):111-8. PubMed ID: 18356630
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [New oral anticancer drug, TS-1 (S-1)--from bench to clinic].
    Shirasaka T; Tsukuda M; Inuyama Y; Taguchi T
    Gan To Kagaku Ryoho; 2001 Jun; 28(6):855-64. PubMed ID: 11432358
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reduction in the plasma clearance rate of warfarin induced by cimetidine.
    Bell WR; Anderson KC; Noe DA; Silver BA
    Arch Intern Med; 1986 Dec; 146(12):2325-8. PubMed ID: 3778066
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Variant CYP2C9 alleles and warfarin concentrations in patients receiving low-dose versus average-dose warfarin therapy.
    Redman AR; Zheng J; Shamsi SA; Huo J; Kelly EJ; Ho RJ; Ritchie DM; Hon YY
    Clin Appl Thromb Hemost; 2008 Jan; 14(1):29-37. PubMed ID: 17895500
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The effect of the microenvironment of head and neck cancers on tumor progression].
    Lukits J
    Magy Onkol; 2009 Mar; 53(1):51-9. PubMed ID: 19318327
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Acquired warfarin resistance and weight-reducing diet.
    Qureshi GD; Reinders TP; Swint JJ; Slate MB
    Arch Intern Med; 1981 Mar; 141(4):507-9. PubMed ID: 7212893
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relationship between international normalized ratio values, vitamin K-dependent clotting factor levels and in vivo prothrombin activation during the early and steady phases of oral anticoagulant treatment.
    D'Angelo A; Della Valle P; Crippa L; Fattorini A; Pattarini E; Viganò D'Angelo S
    Haematologica; 2002 Oct; 87(10):1074-80. PubMed ID: 12368163
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enantiomers of warfarin and vitamin K1 metabolism.
    Choonara IA; Haynes BP; Cholerton S; Breckenridge AM; Park BK
    Br J Clin Pharmacol; 1986 Dec; 22(6):729-32. PubMed ID: 3567019
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The disposition of the enantiomers of warfarin following chronic administration to rats: relationship to anticoagulant response.
    Pratt SK; Winn MJ; Park BK
    J Pharm Pharmacol; 1989 Nov; 41(11):743-6. PubMed ID: 2576040
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics of warfarin enantiomers: a search for intrasubject correlations.
    Wingard LB; O'Reilly RA; Levy G
    Clin Pharmacol Ther; 1978 Feb; 23(2):212-7. PubMed ID: 620483
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Warfarin sodium: steady-state plasma levels and patient age.
    Hotraphinyo K; Triggs EJ; Maybloom B; Maclaine-Cross A
    Clin Exp Pharmacol Physiol; 1978; 5(2):143-9. PubMed ID: 648034
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dynamic interaction between disulfiram and separated enantiomorphs of racemic warfarin.
    O'Reilly RA
    Clin Pharmacol Ther; 1981 Mar; 29(3):332-6. PubMed ID: 7471603
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Smoking and warfarin disposition.
    Bachmann K; Shapiro R; Fulton R; Carroll FT; Sullivan TJ
    Clin Pharmacol Ther; 1979 Mar; 25(3):309-15. PubMed ID: 761442
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interaction of chronic daily warfarin therapy and rifampin.
    O'Reilly RA
    Ann Intern Med; 1975 Oct; 83(4):506-8. PubMed ID: 1166982
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.